Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
Agenus and partner Noetik presented retrospective data at ASCO 2026 showing that Noetik’s AI platform TARIO-2 can identify a subgroup of MSS metastatic colorectal cancer patients with a 64% response rate to Agenus’ BOT+BAL combination. This compares to a 9% response rate in the remaining cohort of 113 patients from the Phase 1b C-800-01 trial, with a hazard ratio of 0.18 for overall survival in the AI-identified group.
Key figures
- Drug Name
- botensilimab (BOT) plus balstilimab (BAL)
- Phase Of Trial
- Phase 1b
- Patient count
- 113
- Hazard ratio os
- 0.18
- Ai subgroup response rate
- 64%
- Non ai subgroup response rate
- 9%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.